Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Tempus AI (NASDAQ:TEM) reported a strong Q2, with its genomics business reaccelerating unit growth to 26% year-over-year, up from 20% in Q1, driven by sales efficiencies and product adoption, while genomics revenue grew over 30% due to reimbursement tailwinds. The company also highlighted continued execution in its data segment, notably with a significant partnership with AstraZeneca and Pathos commencing in Q2. This performance underscores Tempus AI's robust operational momentum and successful commercialization efforts across its key segments.

Analysis

Tempus AI (TEM) demonstrated a significant reacceleration in its core genomics business during Q2, as detailed at the Morgan Stanley Global Healthcare Conference. The company reported a 26% year-over-year increase in genomics unit volume, a notable step-up from the 20% growth seen in Q1, attributing this momentum to enhanced sales efficiencies and broader product adoption. Critically, genomics revenue growth surpassed unit growth, coming in at over 30% due to favorable reimbursement tailwinds, which suggests improving monetization per test and a positive margin outlook. Concurrently, Tempus is showing progress in its data segment by executing on existing agreements and initiating a significant new partnership with AstraZeneca and Pathos in Q2. This combination of accelerating core growth and strategic advancements in high-value data partnerships underscores strong operational execution just over a year since becoming a public company.

Key Decisions for Investors

• The acceleration in genomics unit growth to 26% and revenue growth exceeding 30% provides a strong bullish signal on the company's commercial execution and the favorable impact of reimbursement trends, warranting a positive reassessment of near-term revenue forecasts.
• Investors should closely monitor the progress and future announcements related to the data segment, as the new partnership with a major pharmaceutical player like AstraZeneca serves as a key validation of this business line and could unlock significant, high-margin revenue streams.
• It is crucial to watch for the sustainability of both the accelerated growth rate and the positive reimbursement environment in the upcoming Q3 and Q4 reports to confirm that the Q2 performance represents a new, higher baseline rather than a temporary spike.